SEVER LIFE SCIENCES B.V. WIRD ÜBER IHRE TOCHTERGESELLSCHAFT NORDIC PHARMA, INC. PATIENTENDATEN UND DIE ERGEBNISSE EINER STUDIE ZUR PATIENTENERFAHRUNG MIT LACRIFILL® CANALICULAR GEL, EINER NEUARTIGEN THERAPIE ZUR KONTROLLE DER AUGENOBERFLÄCHE, IM RAHMEN DER TAGUNG DER AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2026 VORSTELLEN

ConferenceLACRIFILL® Canalicular GelPositive

AI Analysis

Summary

Nordic Pharma, a subsidiary of SEVER Life Sciences B.V., will present patient data and patient experience study results for LACRIFILL® Canalicular Gel at the American Academy of Ophthalmology 2026 annual meeting in New Orleans, October 9-12.

Outcome Details

Patient data and patient experience study results presentation

Importance:4/10

Sentiment:

0.30

ophthalmologyconference presentationNordic PharmaLACRIFILLpatient experience study

Related Companies

$AHR

Read the original article

Published by PR Newswire Biotech on October 7, 2026 11:29 PM

Read Original